Skip to content
  1. Stocks
  2. Pharma & Healthcare
  3. Bijoy Hans

Bijoy Hans share price

NSE: BIJHANSPharma & HealthcareMedical Distribution

Bijoy Hans at a glance

With a market capitalisation of ₹292 Cr, it ranks 2066th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Distribution.

Its return on equity was 3.9% in FY25.

Key numbers

Market cap
₹292 CrRank 2066 on NSE
Price to book
1.96×FY25
ROE
3.9%FY25
ROCE
−10.2%FY25
Debt to equity
0FY25
Net profit margin
48.8%FY25
Book value / share
₹11.76FY25

Returns to 22 Oct 2026

Period1 day1 week1 month3 months1 year
Price change—————

Bijoy Hans financials

Annual, ₹ crore unless stated · fiscal years ending March
ItemFY20FY21FY22FY23FY24FY25
Revenue₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Operating profit−₹0 Cr−₹0 Cr−₹0 Cr−₹0 Cr−₹0 Cr−₹0 Cr
Net profit−₹0 Cr−₹0 Cr−₹0 Cr−₹0 Cr−₹0 Cr₹0 Cr
EPS (₹)−₹0.18−₹0.30−₹0.63−₹1.48−₹0.39₹0.45
Cash from operations−₹0 Cr−₹0 Cr−₹0 Cr−₹0 Cr−₹0 Cr₹0 Cr
Total debt₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Shareholders' equity₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹4 Cr

Bijoy Hans vs peers

The listed Pharma & Healthcare companies nearest to Bijoy Hans by market capitalisation.

CompanyPrice1 day1 yearMarket capP/EROE
AAREYDRUGSAarey Drugs & Pharmaceuticals₹111.75−0.84%+31.2%₹317 Cr80.4—
LYKALABSLyka Labs₹82.64−1.99%−13.2%₹299 Cr——
BIJHANSBijoy Hans———₹292 Cr——
ASTONEALABAstonea Labs———₹281 Cr——
AMBALALSAAmbalal Sarabhai Enterprises₹36.20−1.09%—₹277 Cr15.6—
ESPIREEspire Hospital———₹274 Cr——
ZENOTECHZenotech Labs———₹270 Cr——

Ask anything about Bijoy Hans

Pivot answers on the live chart with evidence you can check, and tests strategies against BIJHANS's own history. Try: “Why has BIJHANS moved over the last three months?” · “Backtest a 50-day moving-average crossover on BIJHANS over five years” · “Compare BIJHANS with AAREYDRUGS on margins and valuation”

Start free

Frequently asked questions about Bijoy Hans

What is the market cap of Bijoy Hans?

Bijoy Hans' market capitalisation is ₹292 Cr (₹292 Cr) at the 22 Oct 2026 close, ranking 2066th among the NSE companies Pivot tracks.

What is the ROE and ROCE of Bijoy Hans?

Return on equity was 3.9% in FY25 and return on capital employed was −10.2% in FY25 (standalone figures).

Is Bijoy Hans a debt-free company?

Bijoy Hans is close to debt-free: its debt-to-equity ratio was 0 in FY25.

Who are Bijoy Hans' competitors?

The listed Pharma & Healthcare companies closest to Bijoy Hans by market cap are Aarey Drugs & Pharmaceuticals, Lyka Labs, Astonea Labs, Ambalal Sarabhai Enterprises, Espire Hospital and Zenotech Labs.

Is Bijoy Hans a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Bijoy Hans' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BIJHANS against its own history before risking money. This is analysis, not financial advice.

Sources and method

Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.

More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text